Anupam Rasayan India Ltd - 543275 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations - Draft Letter Of Offer
Anupam Rasayan launched a mandatory open offer to acquire 26% of Bliss GVS Pharma's equity at ₹299 per share, following a prior acquisition of 43.30% stake. The offer is valued at ₹829.03 crore.
Jun 09 2026 19:49:32
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Anupam Rasayan has scheduled an investor meet and plant visit for June 09, 2026, with Prabhudas Liladhar at its Jhagadia GIDC Plant in Gujarat. Discussions will be based on information already in the public domain, with no unpublished price sensitive information intended to be shared. The Q4 FY2024-25 Investor Presentation will be used.
Jun 04 2026 18:22:40
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Credit Rating
Anupam Rasayan's credit ratings for issuer, bank facilities, and NCDs were maintained on 'Rating Watch with Negative Implications' by Ind-Ra. This is due to uncertainty regarding the sustainable capital structure after the acquisition of a controlling stake in Bliss GVS Pharma Limited, which involves significant debt funding.
Jun 03 2026 21:05:09
Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Credit Rating
Crisil Ratings placed Anupam Rasayan's bank facilities and NCDs on 'Rating Watch with Developing Implications'. This action follows the company's announced acquisition of Bliss GVS Pharma and uncertainty surrounding its funding structure.
Jun 03 2026 13:18:03
Anupam Rasayan India Ltd - 543275 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Anupam Rasayan promoter Anand Sureshbhai Desai pledged 31.5 lakh equity shares. This represents 2.77% of the company's total share capital and serves as security for Non-Convertible Debentures (NCDs) issued by the company.
Jun 02 2026 10:26:57
Read More